NFIB and breast carcinoma: We showed that cancer-associated NFIB overexpression provokes genetic alterations that mimic the genomic aberrations in breast carcinomas and that NFIB-evoked genomic abnormalities dynamically evolve to confer growth advantage and therapeutic resistance.